Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial

Many patients with stage 1 hypertension have difficulties to achieve lifestyle changes to avoid the progression of the disease. The use of natural alternatives with demonstrated blood pressure-regulating properties is instrumental at this stage, avoiding the side effects found in some pharmaceutical...

Full description

Bibliographic Details
Main Authors: Marina Boix-Castejón, María Herranz-López, Mariló Olivares-Vicente, Paula Campoy, Nuria Caturla, Jonathan Jones, Juan M. Zazo, Enrique Roche, Vicente Micol
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Journal of Functional Foods
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1756464621002322
id doaj-516ddee6d4254d21bf2d4b1c3d8949f2
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Marina Boix-Castejón
María Herranz-López
Mariló Olivares-Vicente
Paula Campoy
Nuria Caturla
Jonathan Jones
Juan M. Zazo
Enrique Roche
Vicente Micol
spellingShingle Marina Boix-Castejón
María Herranz-López
Mariló Olivares-Vicente
Paula Campoy
Nuria Caturla
Jonathan Jones
Juan M. Zazo
Enrique Roche
Vicente Micol
Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial
Journal of Functional Foods
Pre-hypertension
Continuous blood pressure monitoring
Body fat
Systolic/diastolic blood pressure
Dipper status
Polyphenols
author_facet Marina Boix-Castejón
María Herranz-López
Mariló Olivares-Vicente
Paula Campoy
Nuria Caturla
Jonathan Jones
Juan M. Zazo
Enrique Roche
Vicente Micol
author_sort Marina Boix-Castejón
title Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial
title_short Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial
title_full Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial
title_fullStr Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial
title_full_unstemmed Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trial
title_sort effect of metabolaid® on pre- and stage 1 hypertensive patients: a randomized controlled trial
publisher Elsevier
series Journal of Functional Foods
issn 1756-4646
publishDate 2021-09-01
description Many patients with stage 1 hypertension have difficulties to achieve lifestyle changes to avoid the progression of the disease. The use of natural alternatives with demonstrated blood pressure-regulating properties is instrumental at this stage, avoiding the side effects found in some pharmaceutical drugs. In this context, previous studies have indicated the possibility that a botanical nutraceutical product based on the combination of Lippia citriodora and Hibiscus sabdariffa extracts has hypotensive properties in overweight and obese individuals. Therefore, we aimed to evaluate the antihypertensive properties of this dietary supplement, as well as the effect on anthropometric and circulating parameters in pre-hypertensive and early stage 1 hypertensive patients (n = 84). The nutraceutical product, rich in polyphenolic compounds, has been assessed in a 6-week randomized, double-blind, placebo-controlled trial with pre-hypertensive and early stage 1 hypertensive (non-medicated) individuals. Participants consumed early in the morning in fasting conditions 2 capsules/day containing each one 250 mg of the polyphenolic extracts. Anthropometric and blood parameters as well as punctual and continuous blood pressure monitoring were determined in placebo and experimental groups. As a result and compared to baseline values, volunteers showed a significant reduction of average daily systolic/diastolic blood pressure as well as in daytime diastolic/systolic, nighttime diastolic blood pressure and in % dipper. Intergroup analysis revealed that the consumption of the plant extract resulted in a significant reduction of body fat content (−1.26%; p < 0.05) and nocturnal systolic blood pressure (−16.60 mmHg; p < 0.05) as well as an improvement of the dipper status (3.18%; p < 0.01). In conclusion, these results suggest that the nutraceutical acts as a main regulator of the individual's blood pressure towards healthier values, and therefore may be useful for pre-hypertensive/pre-medicated individuals.
topic Pre-hypertension
Continuous blood pressure monitoring
Body fat
Systolic/diastolic blood pressure
Dipper status
Polyphenols
url http://www.sciencedirect.com/science/article/pii/S1756464621002322
work_keys_str_mv AT marinaboixcastejon effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial
AT mariaherranzlopez effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial
AT mariloolivaresvicente effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial
AT paulacampoy effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial
AT nuriacaturla effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial
AT jonathanjones effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial
AT juanmzazo effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial
AT enriqueroche effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial
AT vicentemicol effectofmetabolaidonpreandstage1hypertensivepatientsarandomizedcontrolledtrial
_version_ 1721306342862356480
spelling doaj-516ddee6d4254d21bf2d4b1c3d8949f22021-07-13T04:09:01ZengElsevierJournal of Functional Foods1756-46462021-09-0184104583Effect of metabolaid® on pre- and stage 1 hypertensive patients: A randomized controlled trialMarina Boix-Castejón0María Herranz-López1Mariló Olivares-Vicente2Paula Campoy3Nuria Caturla4Jonathan Jones5Juan M. Zazo6Enrique Roche7Vicente Micol8Institute of Bioengineering and Department of Applied Biology-Nutrition, University Miguel Hernandez, Alicante Institute for Health and Biomedical Research (ISABIAL Foundation), Alicante, SpainInstituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Miguel Hernández University (UMH), Elche 03202, Alicante, Spain; Corresponding author at: Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche, Universidad Miguel Hernández, Avda. de la Universidad S/N◦, 03202 Elche, Alicante, Spain.Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Miguel Hernández University (UMH), Elche 03202, Alicante, SpainInstituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Miguel Hernández University (UMH), Elche 03202, Alicante, SpainMonteloeder SL, C/Miguel Servet 16, Nave 17, 03203 Elche, Alicante, SpainMonteloeder SL, C/Miguel Servet 16, Nave 17, 03203 Elche, Alicante, SpainRaval Health Center, Elche, Alicante, SpainInstitute of Bioengineering and Department of Applied Biology-Nutrition, University Miguel Hernandez, Alicante Institute for Health and Biomedical Research (ISABIAL Foundation), Alicante, Spain; CIBER, Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, SpainInstituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Miguel Hernández University (UMH), Elche 03202, Alicante, Spain; CIBER, Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, SpainMany patients with stage 1 hypertension have difficulties to achieve lifestyle changes to avoid the progression of the disease. The use of natural alternatives with demonstrated blood pressure-regulating properties is instrumental at this stage, avoiding the side effects found in some pharmaceutical drugs. In this context, previous studies have indicated the possibility that a botanical nutraceutical product based on the combination of Lippia citriodora and Hibiscus sabdariffa extracts has hypotensive properties in overweight and obese individuals. Therefore, we aimed to evaluate the antihypertensive properties of this dietary supplement, as well as the effect on anthropometric and circulating parameters in pre-hypertensive and early stage 1 hypertensive patients (n = 84). The nutraceutical product, rich in polyphenolic compounds, has been assessed in a 6-week randomized, double-blind, placebo-controlled trial with pre-hypertensive and early stage 1 hypertensive (non-medicated) individuals. Participants consumed early in the morning in fasting conditions 2 capsules/day containing each one 250 mg of the polyphenolic extracts. Anthropometric and blood parameters as well as punctual and continuous blood pressure monitoring were determined in placebo and experimental groups. As a result and compared to baseline values, volunteers showed a significant reduction of average daily systolic/diastolic blood pressure as well as in daytime diastolic/systolic, nighttime diastolic blood pressure and in % dipper. Intergroup analysis revealed that the consumption of the plant extract resulted in a significant reduction of body fat content (−1.26%; p < 0.05) and nocturnal systolic blood pressure (−16.60 mmHg; p < 0.05) as well as an improvement of the dipper status (3.18%; p < 0.01). In conclusion, these results suggest that the nutraceutical acts as a main regulator of the individual's blood pressure towards healthier values, and therefore may be useful for pre-hypertensive/pre-medicated individuals.http://www.sciencedirect.com/science/article/pii/S1756464621002322Pre-hypertensionContinuous blood pressure monitoringBody fatSystolic/diastolic blood pressureDipper statusPolyphenols